The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Thrombolytic Therapy

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Thrombolytic Therapy


Psychiatry related information on Thrombolytic Therapy


High impact information on Thrombolytic Therapy


Chemical compound and disease context of Thrombolytic Therapy


Biological context of Thrombolytic Therapy


Anatomical context of Thrombolytic Therapy


Associations of Thrombolytic Therapy with chemical compounds


Gene context of Thrombolytic Therapy


Analytical, diagnostic and therapeutic context of Thrombolytic Therapy

  • Among patients receiving thrombolytic therapy, concomitant pharmacotherapy included intravenous heparin (96.9%), aspirin (84.0%), intravenous nitroglycerin (76.0%), oral beta-blockers (36.3%), calcium channel blockers (29.5%), and intravenous beta-blockers (17.4%) [35].
  • To evaluate the association of smoking with mortality during hospitalization after thrombolytic therapy and 6 months afterward, we analyzed the results of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. METHODS AND RESULTS [36].
  • Application of the F-104 ELISA to monitor the course of Aalpha chain proteolysis in a small study population of patients undergoing thrombolytic therapy for myocardial infarction (n = 14) showed that the loss of fibrinogen-associated F-104 immunoreactivity was a very early marker (within 15 to 30 minutes) of in vivo fibrinogenolysis [37].
  • Immunoblotting studies of the A alpha chain proteolysis that occurs during thrombolytic therapy indicated that alpha C fragments, similar in size and epitope content to those isolated from purified fibrinogen, were released in vivo early during fibrinolytic system activation [38].
  • Finally, patients with acute myocardial infarction who receive intravenous thrombolytic therapy are candidates for predischarge exercise thallium-201 scintigraphy for risk stratification and detection of residual ischemia.(ABSTRACT TRUNCATED AT 250 WORDS)[39]


  1. A comparison of low-molecular-weight heparin with unfractionated heparin for acute pulmonary embolism. The THESEE Study Group. Tinzaparine ou Heparine Standard: Evaluations dans l'Embolie Pulmonaire. Simonneau, G., Sors, H., Charbonnier, B., Page, Y., Laaban, J.P., Azarian, R., Laurent, M., Hirsch, J.L., Ferrari, E., Bosson, J.L., Mottier, D., Beau, B. N. Engl. J. Med. (1997) [Pubmed]
  2. Dynamics of the multidomain fibrinolytic protein urokinase from two-dimensional NMR. Oswald, R.E., Bogusky, M.J., Bamberger, M., Smith, R.A., Dobson, C.M. Nature (1989) [Pubmed]
  3. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. Lincoff, A.M., Califf, R.M., Van de Werf, F., Willerson, J.T., White, H.D., Armstrong, P.W., Guetta, V., Gibler, W.B., Hochman, J.S., Bode, C., Vahanian, A., Steg, P.G., Ardissino, D., Savonitto, S., Bar, F., Sadowski, Z., Betriu, A., Booth, J.E., Wolski, K., Waller, M., Topol, E.J. JAMA (2002) [Pubmed]
  4. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Hacke, W., Kaste, M., Fieschi, C., von Kummer, R., Davalos, A., Meier, D., Larrue, V., Bluhmki, E., Davis, S., Donnan, G., Schneider, D., Diez-Tejedor, E., Trouillas, P. Lancet (1998) [Pubmed]
  5. The role of intracoronary thrombus in unstable angina: angiographic assessment and thrombolytic therapy during ongoing anginal attacks. Gotoh, K., Minamino, T., Katoh, O., Hamano, Y., Fukui, S., Hori, M., Kusuoka, H., Mishima, M., Inoue, M., Kamada, T. Circulation (1988) [Pubmed]
  6. Cost-effectiveness of cardiac rehabilitation after myocardial infarction. Ades, P.A., Pashkow, F.J., Nestor, J.R. Journal of cardiopulmonary rehabilitation. (1997) [Pubmed]
  7. Relation between symptom duration before thrombolytic therapy and final myocardial infarct size. Raitt, M.H., Maynard, C., Wagner, G.S., Cerqueira, M.D., Selvester, R.H., Weaver, W.D. Circulation (1996) [Pubmed]
  8. Age and outcome with contemporary thrombolytic therapy. Results from the GUSTO-I trial. Global Utilization of Streptokinase and TPA for Occluded coronary arteries trial. White, H.D., Barbash, G.I., Califf, R.M., Simes, R.J., Granger, C.B., Weaver, W.D., Kleiman, N.S., Aylward, P.E., Gore, J.M., Vahanian, A., Lee, K.L., Ross, A.M., Topol, E.J. Circulation (1996) [Pubmed]
  9. Beneficial effects of RheothRx injection in patients receiving thrombolytic therapy for acute myocardial infarction. Results of a randomized, double-blind, placebo-controlled trial. Schaer, G.L., Spaccavento, L.J., Browne, K.F., Krueger, K.A., Krichbaum, D., Phelan, J.M., Fletcher, W.O., Grines, C.L., Edwards, S., Jolly, M.K., Gibbons, R.J. Circulation (1996) [Pubmed]
  10. Prevention of arterial reocclusion after thrombolysis with activated protein C. Comparison with heparin in a canine model of coronary artery thrombosis. Sakamoto, T., Ogawa, H., Yasue, H., Oda, Y., Kitajima, S., Tsumoto, K., Mizokami, H. Circulation (1994) [Pubmed]
  11. Low-dose dobutamine echocardiography detects reversible dysfunction after thrombolytic therapy of acute myocardial infarction. Smart, S.C., Sawada, S., Ryan, T., Segar, D., Atherton, L., Berkovitz, K., Bourdillon, P.D., Feigenbaum, H. Circulation (1993) [Pubmed]
  12. Time from onset of symptoms to thrombolytic therapy: a major determinant of myocardial salvage in patients with acute transmural infarction. Mathey, D.G., Sheehan, F.H., Schofer, J., Dodge, H.T. J. Am. Coll. Cardiol. (1985) [Pubmed]
  13. Serial quantitative planar technetium-99m isonitrile imaging in acute myocardial infarction: efficacy for noninvasive assessment of thrombolytic therapy. Wackers, F.J., Gibbons, R.J., Verani, M.S., Kayden, D.S., Pellikka, P.A., Behrenbeck, T., Mahmarian, J.J., Zaret, B.L. J. Am. Coll. Cardiol. (1989) [Pubmed]
  14. Coronary constriction in acute myocardial infarction: role of nitrates. Hackett, D., Davies, G., Maseri, A. Eur. Heart J. (1988) [Pubmed]
  15. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. de Zwaan, C., Kleine, A.H., Diris, J.H., Glatz, J.F., Wellens, H.J., Strengers, P.F., Tissing, M., Hack, C.E., van Dieijen-Visser, M.P., Hermens, W.T. Eur. Heart J. (2002) [Pubmed]
  16. Thrombin stimulation of platelets induces plasminogen activation mediated by endogenous urokinase-type plasminogen activator. Lenich, C., Liu, J.N., Gurewich, V. Blood (1997) [Pubmed]
  17. Hirudin: clinical potential of a thrombin inhibitor. Johnson, P.H. Annu. Rev. Med. (1994) [Pubmed]
  18. Stroke: a double-edged sword for cleaving clots? Anthony, D.C., Perry, V.H. Curr. Biol. (1998) [Pubmed]
  19. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. Kleiman, N.S., Ohman, E.M., Califf, R.M., George, B.S., Kereiakes, D., Aguirre, F.V., Weisman, H., Schaible, T., Topol, E.J. J. Am. Coll. Cardiol. (1993) [Pubmed]
  20. Monitoring of hemostasis parameters during coronary thrombolysis with recombinant tissue-type plasminogen activator. Stump, D.C., Topol, E.J., Chen, A.B., Hopkins, A., Collen, D. Thromb. Haemost. (1988) [Pubmed]
  21. Dipyridamole echocardiography test. A new tool for detecting jeopardized myocardium after thrombolytic therapy. Bolognese, L., Sarasso, G., Bongo, A.S., Rossi, L., Aralda, D., Piccinino, C., Rossi, P. Circulation (1991) [Pubmed]
  22. Thrombolysis is an effective and safe therapy in stuck bileaflet mitral valves in the absence of high-risk thrombi. Shapira, Y., Herz, I., Vaturi, M., Porter, A., Adler, Y., Birnbaum, Y., Strasberg, B., Sclarovsky, S., Sagie, A. J. Am. Coll. Cardiol. (2000) [Pubmed]
  23. Transthoracic and transoesophageal echocardiographic documentation of disappearance of massive right atrial and pulmonary artery thromboemboli after fibrinolytic therapy and normalization of left ventricular dimensions and function. Dall'Aglio, V., Nicolosi, G.L., Zanuttini, D. Eur. Heart J. (1990) [Pubmed]
  24. Color-flow imaging sonography of portal and hepatic vein flow to monitor fibrinolytic therapy with r-TPA for veno-occlusive disease following myeloablative treatment. Sonneveld, P., Laméris, J.S., Cornelissen, J., Ogilvie, A., Löwenberg, B. Bone Marrow Transplant. (1998) [Pubmed]
  25. Thrombolytic therapy in acute occlusion of the intracranial internal carotid artery bifurcation. Jansen, O., von Kummer, R., Forsting, M., Hacke, W., Sartor, K. AJNR. American journal of neuroradiology. (1995) [Pubmed]
  26. Recent trends in acute coronary heart disease--mortality, morbidity, medical care, and risk factors. The Minnesota Heart Survey Investigators. McGovern, P.G., Pankow, J.S., Shahar, E., Doliszny, K.M., Folsom, A.R., Blackburn, H., Luepker, R.V. N. Engl. J. Med. (1996) [Pubmed]
  27. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Topol, E.J. Lancet (2001) [Pubmed]
  28. Unstable angina: status of aspirin and other forms of therapy. Lewis, H.D. Circulation (1985) [Pubmed]
  29. Angiographic features in the infarct-related artery after intracoronary urokinase followed by prolonged anticoagulation. Role of ruptured atheromatous plaque and adherent thrombus in acute myocardial infarction in vivo. Nakagawa, S., Hanada, Y., Koiwaya, Y., Tanaka, K. Circulation (1988) [Pubmed]
  30. Carboxypeptidase R is an inactivator of complement-derived inflammatory peptides and an inhibitor of fibrinolysis. Campbell, W., Okada, N., Okada, H. Immunol. Rev. (2001) [Pubmed]
  31. PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2. Dalla-Volta, S., Palla, A., Santolicandro, A., Giuntini, C., Pengo, V., Visioli, O., Zonzin, P., Zanuttini, D., Barbaresi, F., Agnelli, G. J. Am. Coll. Cardiol. (1992) [Pubmed]
  32. Serum paraoxonase after myocardial infarction. Ayub, A., Mackness, M.I., Arrol, S., Mackness, B., Patel, J., Durrington, P.N. Arterioscler. Thromb. Vasc. Biol. (1999) [Pubmed]
  33. Synthesis and evaluation of imidazole acetic acid inhibitors of activated thrombin-activatable fibrinolysis inhibitor as novel antithrombotics. Barrow, J.C., Nantermet, P.G., Stauffer, S.R., Ngo, P.L., Steinbeiser, M.A., Mao, S.S., Carroll, S.S., Bailey, C., Colussi, D., Bosserman, M., Burlein, C., Cook, J.J., Sitko, G., Tiller, P.R., Miller-Stein, C.M., Rose, M., McMasters, D.R., Vacca, J.P., Selnick, H.G. J. Med. Chem. (2003) [Pubmed]
  34. Transforming growth factor-beta1: a possible signal molecule for posthemorrhagic hydrocephalus? Whitelaw, A., Christie, S., Pople, I. Pediatr. Res. (1999) [Pubmed]
  35. Treatment of myocardial infarction in the United States (1990 to 1993). Observations from the National Registry of Myocardial Infarction. Rogers, W.J., Bowlby, L.J., Chandra, N.C., French, W.J., Gore, J.M., Lambrew, C.T., Rubison, R.M., Tiefenbrunn, A.J., Weaver, W.D. Circulation (1994) [Pubmed]
  36. Significance of smoking in patients receiving thrombolytic therapy for acute myocardial infarction. Experience gleaned from the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. Barbash, G.I., White, H.D., Modan, M., Diaz, R., Hampton, J.R., Heikkila, J., Kristinsson, A., Moulopoulos, S., Paolasso, E.A., Van der Werf, T. Circulation (1993) [Pubmed]
  37. Antipeptide monoclonal antibodies to defined fibrinogen Aalpha chain regions: anti-Aalpha 487-498, a structural probe for fibrinogenolysis. Sobel, J.H., Trakht, I., Pileggi, N., Qi Wu, H. Blood (1998) [Pubmed]
  38. Comparative structural and functional features of the human fibrinogen alpha C domain and the isolated alpha C fragment. Characterization using monoclonal antibodies to defined COOH-terminal A alpha chain regions. Rudchenko, S., Trakht, I., Sobel, J.H. J. Biol. Chem. (1996) [Pubmed]
  39. Role of myocardial perfusion imaging in evaluating thrombolytic therapy for acute myocardial infarction. Beller, G.A. J. Am. Coll. Cardiol. (1987) [Pubmed]
WikiGenes - Universities